0000275053false2019Q3--12-3140546050,00050,00019,33119,20419,33119,204P3YP3Y11.25P90D00002750532019-01-012019-09-30xbrli:shares00002750532019-10-25iso4217:USD00002750532019-09-3000002750532018-12-3100002750532019-07-012019-09-3000002750532018-07-012018-09-30iso4217:USDxbrli:shares00002750532018-01-012018-09-300000275053us-gaap:CommonStockMember2018-12-310000275053us-gaap:RetainedEarningsMember2018-12-310000275053us-gaap:NoncontrollingInterestMember2018-12-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000275053us-gaap:CommonStockMember2019-01-012019-09-300000275053us-gaap:RetainedEarningsMember2019-01-012019-09-300000275053us-gaap:NoncontrollingInterestMember2019-01-012019-09-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000275053us-gaap:CommonStockMember2019-09-300000275053us-gaap:RetainedEarningsMember2019-09-300000275053us-gaap:NoncontrollingInterestMember2019-09-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-3000002750532017-12-3100002750532018-09-300000275053natr:AccruedSeveranceandRentCostsMember2019-09-300000275053natr:AccruedSeveranceandRentCostsMember2018-12-310000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2017-07-11xbrli:pure0000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2017-07-112017-07-110000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2019-09-300000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2018-12-310000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2017-07-112017-07-110000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-09-300000275053natr:A2012IncentivePlanMember2012-12-310000275053natr:A2012IncentivePlanMember2015-01-012015-12-310000275053srt:MaximumMembernatr:IncentivePlan2009Member2019-09-300000275053natr:TimeBasedStockOptionsMembersrt:MaximumMember2019-01-012019-09-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-01-012019-09-300000275053us-gaap:EmployeeStockOptionMember2018-12-310000275053us-gaap:EmployeeStockOptionMember2019-01-012019-09-300000275053us-gaap:EmployeeStockOptionMember2019-09-300000275053natr:A2012IncentivePlanMember2019-01-012019-09-300000275053natr:A2012IncentivePlanMember2019-07-012019-09-300000275053natr:TimeBasedStockOptionsMember2019-07-012019-09-300000275053natr:TimeBasedStockOptionsMember2018-07-012018-09-300000275053natr:TimeBasedStockOptionsMember2019-01-012019-09-300000275053natr:TimeBasedStockOptionsMember2018-01-012018-09-300000275053us-gaap:EmployeeStockOptionMember2018-01-012018-09-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-09-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2018-12-310000275053srt:MinimumMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:MaximumMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:DirectorMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:DirectorMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-09-300000275053srt:DirectorMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2018-12-310000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2018-12-310000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-09-300000275053natr:A2012IncentivePlanMembernatr:TimeBasedRestrictedStockUnitsRSUsMember2019-01-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMembernatr:A2012IncentivePlanMember2019-01-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMembernatr:A2012IncentivePlanMembernatr:NetSalesandOperatingIncomeTargetsMember2019-01-012019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2019-07-012019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2018-07-012018-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2018-12-310000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2019-07-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2018-07-012018-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2019-01-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2018-01-012018-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMembersrt:MaximumMember2019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2019-09-300000275053srt:MinimumMembernatr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-01-012019-09-300000275053srt:MaximumMembernatr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-01-012019-09-30natr:segment0000275053natr:NSPAmericasNSPRussiaCentralandEasternEuropeandNSPChinaMember2019-01-012019-03-310000275053natr:SynergyWorldWideMember2019-01-012019-03-310000275053natr:AsiaSegmentMember2019-07-012019-09-300000275053natr:AsiaSegmentMember2018-07-012018-09-300000275053natr:AsiaSegmentMember2019-01-012019-09-300000275053natr:AsiaSegmentMember2018-01-012018-09-300000275053natr:EuropeSegmentMember2019-07-012019-09-300000275053natr:EuropeSegmentMember2018-07-012018-09-300000275053natr:EuropeSegmentMember2019-01-012019-09-300000275053natr:EuropeSegmentMember2018-01-012018-09-300000275053natr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMember2018-01-012018-09-300000275053country:CN2019-07-012019-09-300000275053country:CN2019-01-012019-09-300000275053country:CN2018-07-012018-09-300000275053country:CN2018-01-012018-09-300000275053country:US2019-07-012019-09-300000275053country:US2018-07-012018-09-300000275053country:US2019-01-012019-09-300000275053country:US2018-01-012018-09-300000275053country:KR2019-07-012019-09-300000275053country:KR2018-07-012018-09-300000275053country:KR2019-01-012019-09-300000275053country:KR2018-01-012018-09-300000275053natr:OtherCountriesMember2019-07-012019-09-300000275053natr:OtherCountriesMember2018-07-012018-09-300000275053natr:OtherCountriesMember2019-01-012019-09-300000275053natr:OtherCountriesMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2019-07-012019-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2018-07-012018-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2019-01-012019-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053country:US2019-09-300000275053country:US2018-12-310000275053us-gaap:NonUsMember2019-09-300000275053us-gaap:NonUsMember2018-12-310000275053natr:AsiaSegmentMember2019-09-300000275053natr:AsiaSegmentMember2018-12-310000275053natr:EuropeSegmentMember2019-09-300000275053natr:EuropeSegmentMember2018-12-310000275053natr:NorthAmericaSegmentMember2019-09-300000275053natr:NorthAmericaSegmentMember2018-12-310000275053natr:LatinAmericaAndOtherSegmentMember2019-09-300000275053natr:LatinAmericaAndOtherSegmentMember2018-12-3100002750532019-01-010000275053us-gaap:AccountingStandardsUpdate201602Member2019-01-010000275053srt:MinimumMember2019-09-300000275053srt:MaximumMember2019-09-30natr:claim0000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember2019-09-300000275053natr:NonIncomeTaxMember2019-09-300000275053natr:NonIncomeTaxMember2018-12-310000275053natr:NonIncomeTaxMembersrt:MinimumMember2019-09-300000275053natr:NonIncomeTaxMembersrt:MaximumMember2019-09-300000275053us-gaap:PendingLitigationMember2019-09-300000275053us-gaap:PendingLitigationMember2018-12-310000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember2019-01-012019-09-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMembersrt:MinimumMember2019-09-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMembersrt:MaximumMember2019-09-300000275053us-gaap:SubsequentEventMember2019-10-012019-11-070000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2019-07-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2019-01-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2019-01-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2019-07-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2018-07-012018-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2018-01-012018-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2018-07-012018-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2018-01-012018-09-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMember2019-09-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMember2018-12-310000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2019-09-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2018-12-310000275053us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000275053us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000275053us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000275053us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-31natr:product_category0000275053srt:MaximumMember2019-01-012019-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________________
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File Number: 001-34483
NATURE’S SUNSHINE PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)
| | | | | | | | |
Utah | | 87-0327982 |
(State or other jurisdiction of | | (IRS Employer |
incorporation or organization) | | Identification No.) |
2901 Bluegrass Boulevard, Suite 100
Lehi, Utah 84043
(Address of principal executive offices and zip code)
(801) 341-7900
(Registrant’s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, no par value | NATR | Nasdaq Capital Market |
Indicate by check mark whether the registrant; (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | |
Large accelerated filer o | | Accelerated filer x |
| | |
Non-accelerated filer o | | Smaller reporting company ☒ |
| | |
| | Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ý.
The number of shares of Common Stock, no par value, outstanding on October 25, 2019, was 19,331,365 shares.
NATURE’S SUNSHINE PRODUCTS, INC.
FORM 10-Q
For the Quarter Ended September 30, 2019
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information included or incorporated herein by reference in this report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. For example, information appearing under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includes forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under “Risk Factors” in Item 1A, and in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, but include the following:
•laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets.
•extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
•legal challenges to the Company's direct selling program or to the classification of its independent distributors;
•impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
•the Company’s ability to attract and retain independent distributors;
•the loss of one or more key independent distributors who have a significant sales network;
•the full implementation of the Company’s joint venture for operations in China with Fosun Industrial Co., Ltd.;
•registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
•cybersecurity threats and exposure to data loss;
•the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations
•reliance on information technology infrastructure;
•the effect of fluctuating foreign exchange rates;
•liabilities and obligations arising from improper activity by the Company’s independent distributors;
•failure of the Company’s independent distributors to comply with advertising laws;
•changes to the Company’s independent distributor compensation plans;
•geopolitical issues and conflicts;
•negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;
•risks associated with the manufacturing of the Company's products;
•uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
•changes in tax laws, treaties or regulations, or their interpretation;
•actions on trade relations by the U.S. and foreign governments.
•product liability claims; and
•the sufficiency of trademarks and other intellectual property rights.
All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, we refer to Nature’s Sunshine Products, Inc., together with our subsidiaries, as "we," "us," "our," "our Company" or “the Company.”
PART I FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)
| | | | | | | | | | | |
| September 30, 2019 | | December 31, 2018 |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 50,530 | | | $ | 50,638 | |
Accounts receivable, net of allowance for doubtful accounts of $405 and $460, respectively | 7,488 | | | 7,751 | |
| | | |
| | | |
Inventories | 45,282 | | | 42,048 | |
Prepaid expenses and other | 5,224 | | | 6,388 | |
Total current assets | 108,524 | | | 106,825 | |
| | | |
Property, plant and equipment, net | 61,052 | | | 64,061 | |
Operating lease right-of-use assets | 24,890 | | | — | |
Investment securities - trading | 1,166 | | | 1,308 | |
Intangible assets, net | 546 | | | 618 | |
Deferred income tax assets | 8,533 | | | 9,056 | |
Other assets | 10,036 | | | 11,148 | |
Total assets | $ | 214,747 | | | $ | 193,016 | |
| | | |
Liabilities and Shareholders’ Equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 4,061 | | | $ | 5,219 | |
Accrued volume incentives and service fees | 19,161 | | | 20,562 | |
Accrued liabilities | 28,787 | | | 34,801 | |
Deferred revenue | 1,324 | | | 1,197 | |
| | | |
Related party note payable | 1,500 | | | 1,530 | |
Income taxes payable | 2,516 | | | 3,378 | |
Current portion of operating lease liabilities | 5,050 | | | — | |
Total current liabilities | 62,399 | | | 66,687 | |
| | | |
Liability related to unrecognized tax benefits | 1,463 | | | 2,192 | |
Long-term portion of operating lease liabilities | 21,061 | | | — | |
| | | |
Deferred compensation payable | 1,166 | | | 1,308 | |
Long-term deferred income tax liabilities | 1,498 | | | 1,556 | |
Other liabilities | 394 | | | 705 | |
Total liabilities | 87,981 | | | 72,448 | |
| | | |
| | | |
| | | |
Shareholders’ equity: | | | |
Common stock, no par value, 50,000 shares authorized, 19,331 and 19,204 shares issued and outstanding, respectively | 135,080 | | | 133,684 | |
Retained earnings (accumulated deficit) | 3,691 | | | (2,072) | |
Noncontrolling interest | 9 | | | 63 | |
Accumulated other comprehensive loss | (12,014) | | | (11,107) | |
Total shareholders’ equity | 126,766 | | | 120,568 | |
Total liabilities and shareholders’ equity | $ | 214,747 | | | $ | 193,016 | |
See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited)
| | | | | | | | | | | |
| Three Months Ended September 30, | | |
| 2019 | | 2018 |
Net sales | $ | 88,524 | | | $ | 88,828 | |
Cost of sales | 22,784 | | | 23,161 | |
Gross profit | 65,740 | | | 65,667 | |
| | | |
Operating expenses: | | | |
Volume incentives | 29,862 | | | 30,511 | |
Selling, general and administrative | 31,177 | | | 31,643 | |
Operating income | 4,701 | | | 3,513 | |
Other loss, net | (1,243) | | | (353) | |
Income before provision for income taxes | 3,458 | | | 3,160 | |
Provision for income taxes | 2,107 | | | 1,821 | |
Net income | 1,351 | | | 1,339 | |
Net income (loss) attributable to noncontrolling interests | 34 | | | (158) | |
Net income attributable to common shareholders | $ | 1,317 | | | $ | 1,497 | |
| | | |
Basic and diluted net income per common share: | | | |
| | | |
| | | |
| | | |
| | | |
Basic earnings per share attributable to common shareholders | $ | 0.07 | | | $ | 0.08 | |
| | | |
| | | |
| | | |
| | | |
Diluted earnings per share attributable to common shareholders | $ | 0.07 | | | $ | 0.08 | |
| | | |
Weighted average basic common shares outstanding | 19,313 | | | 19,164 | |
Weighted average diluted common shares outstanding | 19,662 | | | 19,382 | |
| | | |
| | | |
See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited)
| | | | | | | | | | | |
| Nine Months Ended September 30, | | |
| 2019 | | 2018 |
Net sales | $ | 270,520 | | | $ | 267,436 | |
Cost of sales | 70,078 | | | 70,152 | |
Gross profit | 200,442 | | | 197,284 | |
| | | |
Operating expenses: | | | |
Volume incentives | 92,177 | | | 93,365 | |
Selling, general and administrative | 96,048 | | | 97,339 | |
Operating income | 12,217 | | | 6,580 | |
Other loss, net | (985) | | | (1,420) | |
Income before provision for income taxes | 11,232 | | | 5,160 | |
Provision for income taxes | 5,523 | | | 3,550 | |
Net income | 5,709 | | | 1,610 | |
Net loss attributable to noncontrolling interests | (54) | | | (452) | |
Net income attributable to common shareholders | $ | 5,763 | | | $ | 2,062 | |
| | | |
Basic and diluted net income per common share: | | | |
| | | |
| | | |
| | | |
| | | |
Basic earnings per share attributable to common shareholders | $ | 0.30 | | | $ | 0.11 | |
| | | |
| | | |
| | | |
| | | |
Diluted earnings per share attributable to common shareholders | $ | 0.29 | | | $ | 0.11 | |
| | | |
Weighted average basic common shares outstanding | 19,291 | | | 19,094 | |
Weighted average diluted common shares outstanding | 19,618 | | | 19,406 | |
| | | |
| | | |
See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Amounts in thousands)
(Unaudited)
| | | | | | | | | | | |
| Three Months Ended September 30, | | |
| 2019 | | 2018 |
Net income | $ | 1,351 | | | $ | 1,339 | |
Foreign currency translation gain (loss), net of tax | (656) | | | 12 | |
| | | |
| | | |
Write-off of cumulative translation adjustments | 595 | | | — | |
Total comprehensive income | $ | 1,290 | | | $ | 1,351 | |
| | | | | | | | | | | |
| Nine Months Ended September 30, | | |
| 2019 | | 2018 |
Net income | $ | 5,709 | | | $ | 1,610 | |
Foreign currency translation loss (net of tax) | (1,502) | | | (254) | |
| | | |
Write-off of cumulative translation adjustments | 595 | | | — | |
Total comprehensive income | $ | 4,802 | | | $ | 1,356 | |
See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY
(Amounts in thousands)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | | | Retained Earnings (Accumulated Deficit) | | Noncontrolling Interest | | Accumulated Other Comprehensive Loss | | Total |
| Shares | | Amount | | | | | | | | |
Balance at December 31, 2018 | 19,204 | | | $ | 133,684 | | | $ | (2,072) | | | $ | 63 | | | $ | (11,107) | | | $ | 120,568 | |
Share-based compensation expense | — | | | 1,529 | | | — | | | — | | | — | | | 1,529 | |
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax | 127 | | | (133) | | | — | | | — | | | — | | | (133) | |
| | | | | | | | | | | |
Net income (loss) | — | | | — | | | 5,763 | | | (54) | | | — | | | 5,709 | |
Other comprehensive loss | — | | | — | | | — | | | — | | | (907) | | | (907) | |
Balance at September 30, 2019 | 19,331 | | | $ | 135,080 | | | $ | 3,691 | | | $ | 9 | | | $ | (12,014) | | | $ | 126,766 | |
See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)
| | | | | | | | | | | |
| Nine Months Ended September 30, | | |
| 2019 | | 2018 |
CASH FLOWS FROM OPERATING ACTIVITIES: | | | |
Net income | $ | 5,709 | | | $ | 1,610 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
Provision for doubtful accounts | 4 | | | 155 | |
Depreciation and amortization | 7,533 | | | 7,313 | |
Non-cash lease expense | 3,989 | | | — | |
Share-based compensation expense | 1,529 | | | 1,458 | |
| | | |
Loss (gain) on sale of property, plant and equipment | 17 | | | (4,000) | |
Deferred income taxes | 474 | | | 650 | |
Purchase of trading investment securities | (69) | | | (128) | |
Proceeds from sale of trading investment securities | 392 | | | 610 | |
Realized and unrealized gains on investments | (181) | | | (80) | |
Foreign exchange losses | 597 | | | 1,250 | |
Loss on write-off of cumulative translation adjustment | 595 | | | — | |
Changes in assets and liabilities: | | | |
Accounts receivable | 152 | | | 467 | |
Inventories | (4,074) | | | 462 | |
Prepaid expenses and other current assets | 1,065 | | | (420) | |
Other assets | 469 | | | 897 | |
Accounts payable | (1,073) | | | 88 | |
Accrued volume incentives and service fees | (1,096) | | | 169 | |
Accrued liabilities | (5,277) | | | 7,949 | |
Deferred revenue | 127 | | | (1,334) | |
Lease liabilities | (3,619) | | | — | |
Income taxes payable | (880) | | | (32) | |
Liability related to unrecognized tax benefits | (729) | | | (2,501) | |
Deferred compensation payable | (142) | | | (378) | |
Net cash provided by operating activities | 5,512 | | | 14,205 | |
CASH FLOWS FROM INVESTING ACTIVITIES: | | | |
Purchases of property, plant and equipment | (4,474) | | | (3,959) | |
Proceeds from sale of property, plant and equipment | — | | | 5,072 | |
| | | |
| | | |
Net cash (used in) provided by investing activities | (4,474) | | | 1,113 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | | | |
| | | |
Principal payments of revolving credit facility | (547) | | | (56,853) | |
Proceeds from revolving credit facility | 547 | | | 45,508 | |
Proceeds from related party borrowing | — | | | 1,000 | |
Proceeds from the exercise of stock awards | 60 | | | 664 | |
Tax benefit from stock awards | (193) | | | (578) | |
| | | |
Net cash used in financing activities | (133) | | | (10,259) | |
Effect of exchange rates on cash and cash equivalents | (1,013) | | | (110) | |
Net (decrease) increase in cash and cash equivalents | (108) | | | 4,949 | |
Cash and cash equivalents at the beginning of the period | 50,638 | | | 42,910 | |
Cash and cash equivalents at the end of the period | $ | 50,530 | | | $ | 47,859 | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | | | | |
Cash paid for income taxes, net of refunds | $ | 5,212 | | | $ | 3,700 | |
Cash paid for interest | 63 | | | 220 | |
See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) Basis of Presentation
We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent distributors who uses the products themselves or resells them to consumers.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of September 30, 2019, and for the three and nine-month periods ended September 30, 2019 and 2018. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019.
It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Noncontrolling Interests
Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $34,000 and net loss attributable to the noncontrolling interests of $0.1 million for the three and nine months ended September 30, 2019, respectively. Net losses attributable to the noncontrolling interests were $0.2 million and $0.5 million for the three and nine months ended September 30, 2018, respectively. As of September 30, 2019 and December 31, 2018, noncontrolling interests were $9,000 and $0.1 million, respectively.
Restructuring Related Accruals and Expenses
We recorded $0.4 million and $2.4 million of restructuring related expenses during the three and nine months ended September 30, 2019, respectively. We recorded $0.7 million restructuring related expenses during the three and nine months ended September 30, 2018. Accrued severance and restructuring related costs were $0.5 million and $0.3 million as of September 30, 2019 and December 31, 2018, respectively.
During the second quarter of 2018, we announced the retirement of our Chief Executive Officer. As a result, we recorded $0 and $1.5 million of transition-related expenses during the three and nine months ended September 30, 2018. As of September 30, 2019 and December 31, 2018, accrued transition costs were $0.5 million and $1.0 million, respectively.
During the third quarter of 2019, we wrote-off cumulative translation adjustments from the closure of a market that resulted in a loss of $0.6 million. This loss is included in Other loss, net, within the Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2019.
Recent Accounting Pronouncements
We adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842): Accounting for Leases effective January 1, 2019. This update requires that lessees recognize right-of-use assets and lease liabilities that are measured at the present value of the future lease payments at lease commencement date. See Note 8 - Leases for additional disclosure of the adoption of Topic 842.
In February 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Effects from Accumulated Other Comprehensive Income. This update allows a reclassification of stranded tax effects, resulting from the Tax Cuts and Jobs Act 2017, from
accumulated other comprehensive income to retained earnings. This ASU is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of ASU 2018-02 did not have a material effect on our results of operations, consolidated financial statements and footnote disclosures.
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.
(2) Inventories
The composition of inventories is as follows (dollar amounts in thousands):
| | | | | | | | | | | |
| September 30, 2019 | | December 31, 2018 |
Raw materials | $ | 12,139 | | | $ | 10,410 | |
Work in progress | 1,797 | | | 1,524 | |
Finished goods | 31,346 | | | 30,114 | |
Total inventories | $ | 45,282 | | | $ | 42,048 | |
(3) Investment Securities - Trading
Our trading securities portfolio totaled $1.2 million at September 30, 2019, and $1.3 million at December 31, 2018, and generated gains of $8,000 and $70,000 for the three months ended September 30, 2019 and 2018, respectively, and $181,000 and $103,000 for the nine months ended September 30, 2019 and 2018, respectively.
(4) Revolving Credit Facility
On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million, that matures on July 11, 2020 (the “Credit Agreement”). We pay interest on any borrowings under the Credit Agreement at LIBOR plus 1.25 percent (3.29 percent and 3.73 percent as of September 30, 2019 and December 31, 2018), and an annual commitment fee of 0.2 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified prior outstanding borrowings as non-current on our condensed consolidated balance sheet. At September 30, 2019, there was no outstanding balance under the Credit Agreement.
The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency, leverage, and minimum EBITDA. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable balance, inventory balance and other assets. As of September 30, 2019, we were in compliance with the debt covenants set forth in the Credit Agreement.
(5) Net Income Per Share
Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.
Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and nine months ended September 30, 2019 and 2018 (dollar and share amounts in thousands, except for per share information):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | | | Nine Months Ended September 30, | | |
| 2019 | | 2018 | | 2019 | | 2018 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net income attributable to common shareholders | $ | 1,317 | | | $ | 1,497 | | | $ | 5,763 | | | $ | 2,062 | |
| | | | | | | |
Basic weighted average shares outstanding | 19,313 | | | 19,164 | | | 19,291 | | | 19,094 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Basic earnings per share attributable to common shareholders | $ | 0.07 | | | $ | 0.08 | | | $ | 0.30 | | | $ | 0.11 | |
| | | | | | | |
Diluted shares outstanding: | | | | | | | |
Basic weighted-average shares outstanding | 19,313 | | | 19,164 | | | 19,291 | | | 19,094 | |
Stock-based awards | 349 | | | 218 | | | 327 | | | 312 | |
Diluted weighted-average shares outstanding | 19,662 | | | 19,382 | | | 19,618 | | | 19,406 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Diluted earnings per share attributable to common shareholders | $ | 0.07 | | | $ | 0.08 | | | $ | 0.29 | | | $ | 0.11 | |
| | | | | | | |
Dilutive shares excluded from diluted-per-share amounts: | | | | | | | |
Stock options | 439 | | | 105 | | | 439 | | | 105 | |
| | | | | | | |
Anti-dilutive shares excluded from diluted-per-share amounts: | | | | | | | |
Stock options | 218 | | | 1,036 | | | 243 | | | 1,011 | |
Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.
(6) Capital Transactions
Share-Based Compensation
During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.
We also maintain a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares.
Stock Options
Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.
Stock option activity for the nine-month period ended September 30, 2019, is as follows (amounts in thousands, except per share information):
| | | | | | | | | | | |
| Number of Shares | | Weighted Average Exercise Price Per Share |
Options outstanding at December 31, 2018 | 1,114 | | | $ | 12.23 | |
Granted | 25 | | | 8.72 | |
Forfeited or canceled | (793) | | | 12.87 | |
Exercised | (27) | | | 2.35 | |
Options outstanding at September 30, 2019 | 319 | | | 11.21 | |
During the nine months ended September 30, 2019, we granted options to purchase 25,000 shares of common stock under the 2012 Stock Incentive Plan to one member of our Board of Directors. These options were issued with an exercise price of $8.72 per share and a grant date fair value of $3.44 per share, with an expected life of five years, risk-free interest rate of 1.5 percent, and expected volatility of 43.2 percent.
Share-based compensation expense from time-based stock options for the three-month periods ended September 30, 2019 and 2018, was approximately $0.1 million and $0.1 million, respectively. Share-based compensation expense from time-based stock options for the nine-month periods ended September 30, 2019 and 2018, was approximately $0.1 million and $0.2 million, respectively. As of September 30, 2019 and December 31, 2018, there was no unrecognized share-based compensation expense related to the grants described above.
At September 30, 2019, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 319,000 shares of common stock was $0.1 million. At December 31, 2018, the aggregate intrinsic value of outstanding and exercisable options to purchase 1,114,000 shares of common stock was $0.2 million.
For the nine-month periods ended September 30, 2019 and 2018, we issued 27,000 and 99,000 shares of common stock upon the exercise of stock options at an average exercise price of $2.35 and $6.10 per share, respectively. The aggregate intrinsic value of options exercised during the nine-month periods ended September 30, 2019 and 2018, was $0.2 million and $0.4 million, respectively. For the nine-month periods ended September 30, 2019 and 2018, the Company recognized $0.1 million and $0.1 million of tax benefits from the exercise of stock options, respectively.
As of September 30, 2019 and December 31, 2018, we did not have any unvested performance-based stock options outstanding.
Restricted Stock Units
Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At September 30, 2019 and December 31, 2018, there were 81,000 and 80,000 vested RSUs, respectively, granted to the Board of Directors with a restriction period.
Restricted stock unit activity for the nine-month period ended September 30, 2019, is as follows (amounts in thousands, except per share information):
| | | | | | | | | | | |
| Number of Shares | | Weighted Average Grant Date Fair Value |
Restricted Stock Units outstanding at December 31, 2018 | 1,058 | | | $ | 8.87 | |
Granted | 333 | | | 7.23 | |
Forfeited | (389) | | | 9.88 | |
Issued | (113) | | | 10.73 | |
Restricted Stock Units outstanding at September 30, 2019 | 889 | | | 7.57 | |
During the nine-month period ended September 30, 2019, we granted 333,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $8.59 per share and vest in annual installments over a three-year period from the grant date or according to the restrictions for the Board of Directors noted above. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $4.38 per share and vest upon achieving share-priced targets over a three-year period from the grant date.
Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 13.4 percent for a common share.
Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50 percent, and a range of risk-free rates between 2.1 percent and 2.9 percent.
Share-based compensation expense for RSUs for the three-month periods ended September 30, 2019 and 2018, was approximately $0.5 million and $0.3 million, respectively. Share-based compensation expense from RSUs for the nine-month periods ended September 30, 2019 and 2018, was approximately $1.1 million and $1.3 million, respectively. As of September 30, 2019 and December 31, 2018, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $1.5 million and $1.8 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.9 years.
Share-based compensation expense related to performance-based RSUs for the three-month periods ended September 30, 2019 and 2018, was $0.1 million and $0, respectively. Share-based compensation expense related to performance-based RSUs for the nine-month periods ended September 30, 2019 and 2018, was $0.4 million and $0, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would recognize up to $1.9 million of potential share-based compensation expense. We currently expect to recognize an additional $0.9 million of that potential share-based compensation expense.
The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 23,000 and 55,000 shares for the nine-month periods ended September 30, 2019 and 2018, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.
(7) Segment Information
We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.
Historically, our operating segments were based on brand, customer base, geographical operations with three operating business segments under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China), and one operating business segment under the Synergy® WorldWide brand.
During the second quarter of 2019, we realigned into geographic focused operating business segments across brands to further align regional strategies and drive synergies in product, organizational and go-to-market strategies in local markets. Our internal reporting structure was reorganized to support the new reporting segments and the chief operating decision maker now reviews the operating results of the four segments utilizing a geographic focused format. The presentation of the comparative information has been recast to conform to the 2019 presentation.
Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.
Reportable business segment information is as follows (dollar amounts in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | | | Nine Months Ended September 30, | | |
| 2019 | | 2018 | | 2019 | | 2018 |
Net sales: | | | | | | | |
Asia | $ | 33,717 | | | $ | 34,063 | | | $ | 102,475 | | | $ | 97,593 | |
Europe | 14,640 | | | 13,076 | | | 45,312 | | | 41,601 | |
North America | 34,161 | | | 35,578 | | | 105,304 | | | 109,201 | |
Latin America and Other | 6,006 | | | 6,111 | | | 17,429 | | | 19,041 | |
Total net sales | 88,524 | | | 88,828 | | | 270,520 | | | 267,436 | |
| | | | | | | |
Contribution margin (1): | | | | | | | |
Asia | 16,236 | | | 16,250 | | | 48,638 | | | 45,891 | |
Europe | 4,865 | | | 4,035 | | | 14,692 | | | 13,744 | |
North America | 12,169 | | | 12,337 | | | 37,587 | | | 36,929 | |
Latin America and Other | 2,608 | | | 2,534 | | | 7,348 | | | 7,355 | |
Total contribution margin | 35,878 | | | 35,156 | | | 108,265 | | | 103,919 | |
| | | | | | | |
Selling, general and administrative expenses (2) | 31,177 | | | 31,643 | | | 96,048 | | | 97,339 | |
Operating income | 4,701 | | | 3,513 | | | 12,217 | | | 6,580 | |
| | | | | | | |
Other loss, net | (1,243) | | | (353) | | | (985) | | | (1,420) | |
Income before provision for income taxes | $ | 3,458 | | | $ | 3,160 | | | $ | 11,232 | | | $ | 5,160 | |
_________________________________________
(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
(2) Service fees in China totaled $2.8 million and $7.3 million for the three and nine-month periods ended September 30, 2019, respectively, compared to $2.7 million and $6.7 million for the three and nine-month periods ended September 30, 2018. These service fees are included in selling, general and administrative expenses.
From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and nine-month periods ended September 30, 2019 and 2018, as follows (dollar amounts in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | | | Nine Months Ended September 30, | | |
| 2019 | | 2018 | | 2019 | | 2018 |
Net sales: | | | | | | | |
United States | $ | 31,579 | | | $ | 33,182 | | | $ | 97,734 | | | $ | 101,322 | |
South Korea | 15,226 | | | 18,271 | | | 52,677 | | | 52,463 | |
Other | 41,719 | | | 37,375 | | | 120,109 | | | 113,651 | |
| $ | 88,524 | | | $ | 88,828 | | | $ | 270,520 | | | $ | 267,436 | |
Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | | | Nine Months Ended September 30, | | |
| 2019 | | 2018 | | 2019 | | 2018 |
Asia | | | | | | | |
General health | $ | 9,450 | | | $ | 8,290 | | | $ | 28,287 | | | $ | 23,046 | |
Immune | 105 | | | 228 | | | 462 | | | 663 | |
Cardiovascular | 9,997 | | | 11,927 | | | |